Home » FDA Approves Surrogate Endpoint for ARYx Anticoagulant
FDA Approves Surrogate Endpoint for ARYx Anticoagulant
January 8, 2010
An additional trial in a real world setting comparing ARYx Therapeutics’ novel anticoagulant agent, tecarfarin, with warfarin, the leading anticoagulant,
could be enough to establish tecarfarin’s superiority, ARYx says.